A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer｜臨床研究

PALLAS医師主導国際共同治験（JBCRG-24） GLOBAL 本研究は医師主導の国際共同治験で、依頼元であるオーストリアの研究団体ABCSG（Austria Breast Cancer Study Group）との契約に基づきBIG（Breast International Group）からの資金提供を受けて実施しています。: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

目的: To compare invasive disease-free survival (iDFS) for the combination of at least 5 years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2- invasive early breast cancer (EBC).

実施医療機関

臨床研究詳細